Skip to main content

Table 3 Univariable analysis of secondary outcomes

From: Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: a cohort study

Characteristics

NAB (n = 59)

Standard care (n = 274)

P value

VAP incidence after the onset of Candida colonisation (per 1000 ICU days)

6.5

5.5

0.64

Number of Candida recolonisation episodes*

1 (2)

15 (6)

0.32

Length of stay in ICU after onset of Candida colonisation

23 (12–30)

14 (10–23)

0.004

Length of stay in ICU after NAB start

14 (7–25)

NA

NA

ICU Mortality

10 (17)

54 (20)

0.62

  1. *The denominators for the calculation of the numbers of Candida recolonisation events in the NAB and standard care group are 58 and 259 initial colonisation episodes, respectively. ICU, intensive care unit; NA, not applicable; NAB, nebulised amphotericin B; VAP, ventilator-associated pneumonia. Data are presented as medians (interquartile range (IQR)) or absolute numbers (%), except for the ventilator-associated pneumonia rate that is presented as the number per 1,000 ICU days.